Moxifloxacin, a new 8-methoxyfluoroquinolone, was evaluated in a large community-based study involving 16 007 patients over a 9-month period. This study was designed as a large post-marketing observational study of the speed, efficacy and tolerability of moxifloxacin when used in clinical practice for the treatment of community-acquired bacterial pneumonia, or acute exacerbations of chronic bronchitis. Physicians and patients were specifically questioned about overall efficacy and safety as well as symptom relief. According to physicians' assessments 96.3% of patients were cured or improved after moxifloxacin treatment. Symptom relief ('feeling better') occurred in almost 70% of patients by day 3 and only 2.3% reported an adverse drug reaction. No individual adverse drug reaction was reported at a frequency above 1%. Among the 209 events considered as serious, only 34 were regarded as possibly or probably related to therapy. There were no moxifloxacin-related clinically relevant cases of phototoxicity, hepatotoxicity or cardiotoxicity. Overall, 92.1% of patients considered moxifloxacin to have been beneficial.
Introduction
The impact of respiratory infections on individuals and society is immense and is growing as the population ages. Lower respiratory tract infections, in particular, are major causes of morbidity and mortality.
These infections include acute exacerbations of chronic bronchitis (AECB) and community-acquired pneumonia (CAP). Of the two conditions, AECB is more prevalent, occurring in around 14% of the US population, but the incidence varies with country. 1, 2 Moreover, AECB is part of the constellation of conditions comprising chronic obstructive pulmonary disease (COPD), which has shown a consistent increase in incidence over the past 40 years, 
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particularly in younger women, with the age group 45 -60 years seeing significant increases. 3 The costs associated with AECB in terms of morbidity and mortality are considerable. In Germany the cost of AECB is 12 working days per patient lost annually with an economic impact of US$10 billion (Euro 8 billion). The incidence of chronic bronchitis in Germany is 46% of the > 65 years age group, with an average of 2.4 acute exacerbations per patient each year. The mortality associated with this debilitating disease is 11 per 100 000/year. 4 Data from the 1993 National Health Interview Survey in the USA, based on selfreported disease, indicate that almost 14 million Americans have chronic bronchitis and 2 million have emphysema. 5 It is generally believed that up to 50% of cases are undiagnosed and that COPD may present in around 30 million patients. 6 The annual direct medical costs of COPD in the USA are over US$15 billion, with outpatient and emergency care comprising some 40% of the total costs and hospitalizations accounting for US$8 billion each year. 7, 8 COPD/AECB accounts for almost 120 million days of restricted activity in the USA annually. 9 In Germany there are 350 000 -500 000 cases of CAP annually (429 -613/ 100 000 population) with the rate varying by age group. Among those over 65 years there are 25 -44 cases per 1000/year with an overall average of 1 -11.6 cases per 1000/year. The mortality rate is 2% with a hospitalization rate of 6 -24%, of whom 22 -57% are admitted to intensive care units. 4 Community-acquired pneumonia is the sixth leading cause of death in the USA, with an estimated 4 million cases each year, 10 of whom 600 000 are hospitalized due to their illness. Age affects the attack rate and the individual and societal costs. The 'working age group' experience 1 -5 cases per 1000 persons, whereas among the 0 -4-year age group there are 12 -18 cases per 1000 persons.
The majority of these infections are initially managed by the primary care physician or community specialist, and mainly macrolide and β-lactam antimicrobials are prescribed in Germany. As appreciation of the impact of these diseases grows, among patients and their employers, the management of AECB and CAP will need to be reassessed. Normally, treatment courses last 10 -14 days with patients feeling better by day 7 or 8. Often, they stop taking their medications at this time, which may contribute to the exacerbation of bacterial resistance in some areas. In Germany 14 -24% of Streptococcus pneumoniae strains are macrolide resistant and 13% are penicillin resistant, a marked rise since 1995 when macrolide non-susceptibility was 5%.
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A new 8-methoxyfluoroquinolone, moxifloxacin, was approved in Germany in June 1999 for the treatment of AECB, CAP and acute sinusitis in single daily doses of 400 mg for 5 -10 days. Moxifloxacin is the first truly anti-pneumococcal quinolone to be approved in Germany, and we report a large-scale, community-based assessment of its efficacy and safety for the treatment of respiratory infections presenting to the primary physician. The patients' and physicians' satisfaction with the treatment was also evaluated. 
Patients and methods
PATIENTS
TREATMENTS
Patients with a diagnosis of AECB or CAP were prescribed moxifloxacin, by their physician, mostly according to the following regimens: (i) for acute exacerbation of chronic bronchitis, 400 mg once daily for 5 days; (ii) for community-acquired pneumonia, 400 mg once daily for 10 days.
ASSESSMENTS
Patients underwent a routine physical examination on diagnosis, and a history of signs and symptoms was taken. There were no laboratory or radiological investigations. Patients were asked to complete a daily diary questionnaire during therapy.
The questionnaires were returned 4 weeks after therapy. At follow-up visits and up to 4 -6 weeks after therapy, patients were carefully questioned about any adverse events or reactions. All forms from the physicians and patients were collated and analysed by a clinical research organization.
The questions answered by physicians and patients, in addition to the standard demographic and history queries, are listed in Table 1 . All returned questionnaires were checked for completion and plausibility. Specific 'hidden' questions about adverse events were carefully evaluated to ensure all possible safety characteristics were recognized. As the study was an open, noncomparative assessment of the efficacy and safety of moxifloxacin, only descriptive statistics were applied. 
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Results
PATIENTS
A total of 16 007 patients were enrolled into the study, approximately equal proportions of males and females (51.0% : 48.7% [0.3% not known]). The age distribution of these patients was typical of those who experience lower respiratory tract infections: 72.9% were > 40 years old, and 32.1% were > 60 years old. Although it is not recommended to prescribe fluoroquinolones to those of < 18 years of age, 152 patients below this age did receive moxifloxacin (14 of < 14 years, 39 of 14 -< 16 years, and 99 of 16 -< 18 years).
Acute exacerbations of chronic bronchitis was the most frequent diagnosis, affecting 49.8% of patients, while 27.6% had a diagnosis of CAP, 13.8% had 'acute bronchitis' and 7.0% had acute (maxillary) sinusitis. These data demonstrate the preponderance of chronic bronchial disease in the community, underscoring the need to manage the condition aggressively before the patient deteriorates further with significantly compromised lung function.
The vast majority of patients had moderate or severe disease (63.7% and 32.7%, respectively). The distribution of disease by gender is shown in Table 2 . Seven thousand, three hundred and fourteen patients fulfilled the COPD criteria of the American Thoracic Society, 12 of whom 84.9%
had received an antibiotic for their last AECB. A single antibiotic was prescribed in 6203 cases, most often either a macrolide (37.5%), tetracycline (14.6%), penicillin (5.5%), cephalosporin (25.9%) or a fluoroquinolone (10.6%). For the current disease 91.5% of the patients had no antibiotic pretreatment before moxifloxacin. The onset of acute symptoms for all patients is shown in Fig. 1 ; the majority of patients (73.9%) presented to their physician by day 4, reflecting the moderate-to-severe nature of the infections. Some of both the AECB and the CAP patients had experienced multiple infections in the preceding 12 months. These recurrences were more common in the AECB group, reflecting the chronic nature of the condition; however, at least 15.5% of CAP patients had also reported two or more respiratory infections in the previous year. The repetitious nature of the infections is shown in Fig. 2 .
The duration of the treatment varied according to diagnosis; 43.1% of the patients received and took 5 days of 400 mg moxifloxacin once daily. Treatment duration was ≤ 10 days in 93.6% of patients and 11 -14 days in 5.0% of patients. Patients took their medication at varying times, 72.2% taking the tablet in the morning, 16.7% taking it at noon and 9.0% taking it in the evening. The remaining 2.1% did not report when they took their medication.
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The physicians' evaluations of 7957 patients with AECB and 4409 patients with CAP are shown in Figs 3 and 4 , respectively. The mean times to improvement of the patients' condition, for AECB and CAP, were 3.1 and 3.3 days, respectively.
Moxifloxacin was well tolerated by most patients in that only 2.1% discontinued therapy prematurely (1.1% due to an adverse event and 0.7% due to a lack of clinical response).
Within a 4 -6-week follow-up period, 82.3% of patients returned to their physician. Overall, the median number of visits was 2.0, mean 2.6 visits. Reinfection caused 3.2% of patients to revisit their physicians: 5.3% of severe AECB cases relapsed compared with 2.0% of severe CAP patients.
The physicians' overall assessments of moxifloxacin therapy for 16 007 patients were cure and improvement, 96.3%: while medication tolerability was very good or good in 95.5%, and sufficient in 1.5%. Table 3 shows the specific evaluations of efficacy by diagnosis. Once-daily doses of moxifloxacin led to a high compliance rate of 97.3%, with only 0.6% not compliant (1.4% not assessable).
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PATIENTS' ASSESSMENTS
The patient diary was completed every day during treatment. The physician assessments were consistent with those of the patients. The five-symptom responses are shown in Fig. 5 . As symptoms diminished or disappeared the rate of reporting by patients decreased day by day; fever was the quickest to respond, with typical bronchitis problems of cough and fatigue taking longer to diminish. Overall, after 3 days of moxifloxacin therapy 69.7% of patients 
Treatment of community-acquired respiratory infections
reported 'feeling better'; by days 5 and 10 these proportions had increased to 89.8% and 93.8%, respectively. There was little difference between the rates of response of patients with different diagnoses.
When asked whether moxifloxacin had been beneficial, 92.1% of patients responded favourably, while only 3.3% were not satisfied. Of those who answered the questions pertaining to relapse within a month, over 91% did not have a reinfection.
SAFETY AND TOLERABILITY
Of the 16 007 patients enrolled in the study, 918 reported at least one event. A total of 1302 events were reported, with 597 events of possible, probable or unknown relationship to moxifloxacin (2.3% of the enrolled patients). Among the total of 209 events recorded as serious (affecting 0.9% of enrolled patients) 42 were regarded as having possible, probable or unknown relationship to therapy (affecting 0.16% of enrolled patients). The majority (57.7%) of those reporting an event were female.
The most frequent events considered to be related to moxifloxacin therapy were nausea (0.47%), diarrhoea (0.38%), vertigo (0.22%), vomiting (0.18%), abdominal pain (0.16%) and headache (0.16%). All of these are typical adverse events seen in patients on antimicrobial therapy.
Serious adverse events were rare: a total of 209 such events occurred in 150 patients. Among these 209 events, 42 events in 32 patients were regarded as serious adverse drug reactions; the most common body systems involved were the digestive tract (13 patients, 0.08%) and the respiratory and cardiovascular systems (six patients each).
In the light of the recent withdrawals of fluoroquinolones from the market, special attention was paid to cardiac, phototoxic and hepatic events. Seventy-seven patients reported 88 cardiac events and 36 were considered by the physicians either probably or possibly related to moxifloxacin therapy (0.22%). After reviewing the data from this large study by an external CEC (Critical Event Committee), they could not find evidence of any documented arrhythmia that could be related to moxifloxacin treatment nor any case of treatment-emerging QT prolongation with a plausible relation to moxifloxacin. No case of phototoxicity was reported by the physicians and no evidence was found in the data.
Hepatological events were also carefully analysed, but only four were reported in total, of which three were considered by the physicians probably or possibly related to moxifloxacin therapy. Two of these events were mild, transient elevations in liver function tests and one was a case of transient jaundice.
During the study period, 13 patients (eight females and five males) died (0.08%), all aged ≥ 62 years. In no instance was moxifloxacin considered to have contributed to the death.
Discussion
Various expert groups have reported that the incidence of lower respiratory tract infections, including AECB and CAP, is increasing. In particular AECB is becoming a major issue in females aged 40 -55 years of age. Clearly, early and continued cigarette smoking is a major factor. The impact of chronic and steadily debilitating diseases such as AECB on the individual and society is only recently becoming appreciated. Antimicrobial treatment for many of these infections is often selected on a cost basis, however, even though the costs of antimicrobials are such a small part of the overall management costs, and physicians are encouraged to prescribe cheap, old first-line agents such as penicillin, tetracyclines and early macrolides. Defining the cost-effectiveness of an antimicrobial in AECB and CAP is difficult, but agents that cost little to buy but have limited efficacy may cause patients to miss work or to need hospitalization, and are thus less costeffective than more expensive agents that cure the patient more rapidly.
Other endpoints that can also be considered in assessing cost-effectiveness include the duration of the infection-free period, the prevention of hospitalization, the maintenance of airways patency thus reducing the need for other medications, and the prevention or slowing of antimicrobial resistance.
In accordance with regulatory requirements most evaluations of antimicrobials occur 5 -10 days after the end of therapy, but improved understanding of antimicrobial mechanisms suggests that assessments should also be made during each of the first 5 days of therapy. The action of β-lactams is independent of their concentrations such that the length of time for which serum/tissue concentrations exceed its minimum inhibitory concentration (MIC) for the pathogen is the most important pharmacodynamic parameter. Fluoroquinolones, on the other hand, show a concentrationdependent mechanism: for rapid eradication of pathogens the extent to which fluoroquinolone concentrations in serum/tissue exceed the MIC, the C max :MIC ratio, is important. Ideally this ratio should exceed 8 -10; moxifloxacin achieves values of over 40 and 300 for Streptococcus pneumoniae and Haemophilus influenzae, respectively. 13 These are the highest values reported with the fluoroquinolones. 13 It has been shown that bacteria which are not killed evoke a host response which in itself causes inflammation and destruction of the host tissues. Values higher than those recommended may lead to an even more rapid elimination of the pathogen than by other antimicrobials. Thus such rapid eradication can lead to quicker reduction of the host defenses with subsequent faster decrease in signs and symptoms. Additional benefits from fluoroquinolones, such as moxifloxacin, have been reviewed. 14 The results from the present large, community-based study, which enrolled over 16 000 patients, demonstrate that moxifloxacin elicits a clinical cure or improvement in 96.9% and 97.5% of patients with AECB and CAP, respectively. Moreover, this cure occurs rapidly, as the five cardinal signs and symptoms of respiratory infections were significantly reduced in almost 70% of patients within 3 days.
This finding has been corroborated in two other studies involving moxifloxacin; 15, 16 both trials compared 5 days' moxifloxacin (400 mg once daily) with 5 days' azithromycin (500/250 mg once daily) in AECB. DeAbate et al. 15 observed the typical end-of-therapy equivalency results of 88% and 86% for clinical efficacy and 95% and 94% for bacterial eradication for moxifloxacin and azithromycin, respectively. One centre conducted daily detailed bacteriological assessments and demonstrated faster eradication with moxifloxacin, 63% versus 48%, P = 0.11. By day 5 no moxifloxacin-treated patient was still infected, whereas the original pathogen was still present in four patients in the azithromycin group.
A second study by Kreis et al. 16 was not a classical phase III trial, but was similar in design to the present study (i.e. conducted in primary care with 'real-world' criteria). Over 400 patients were randomized to receive either moxifloxacin or azithromycin. The study was powered to show clinical equivalence; however, there was a significant difference in symptom relief in favour of moxifloxacin, with 40% versus 27% reporting a positive response by day 3 (P = 0.03). These patients reported more rapid symptomatic relief with moxifloxacin compared with azithromycin, at least 66% responded well by day 3 compared with day 5 or beyond for patients treated with azithromycin. The 7957 AECB patients treated in the study corroborate these earlier findings. In addition to the rapid symptomatic relief and faster return to normal afforded by moxifloxacin, patients were also satisfied with therapy because they had fewer adverse drug reactions. The low rate of premature discontinuations is similar to that with many other antimicrobials prescribed in the community.
The drug-related adverse events reported were typical, anticipated antimicrobial adverse effects such as nausea, diarrhoea and headache. Among this very large patient base, of 16 007 patients, there were no moxifloxacinrelated, clinically relevant cases of phototoxicity, hepatotoxicity or cardiotoxicity. Physicians and patients reported a very high rate of compliance and satisfaction, probably related to rapid symptom relief, high cure rates and low incidence of adverse events.
Moxifloxacin, at 400 mg once daily for 5 -10 days showed a very high rate of clinical efficacy, a low rate of adverse drug reactions, a rapid symptomatic response, and a low hospitalization and relapse rate. These are the hallmarks of a cost-effective antimicrobial for use in community respiratory infections such as AECB and CAP.
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